TY - JOUR
T1 - Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma
AU - McClelland, Shearwood
AU - Hatfield, Jess
AU - Degnin, Catherine
AU - Chen, Yiyi
AU - Mitin, Timur
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/6/15
Y1 - 2019/6/15
N2 - Background: Localized breast angiosarcoma (LBA) is a rare condition with no prospective clinical trials guiding the management of afflicted patients. Management of LBA and the resulting outcomes on a nationwide scale has not been previously examined. Methods: The National Cancer Data Base (NCDB) from 2004 to 2014 identified resected LBA patients. Treatment patterns were compared between three time periods (2004–2007, 2008–2011, and 2012–2014). Demographic and tumor characteristics, as well as treatments received—extent of surgery and adjuvant therapies—were analyzed for association with overall survival after adjustment for covariates. Results: 826 resected localized breast angiosarcoma patients were identified. Mastectomy was the most common surgical approach (86%); over 60% of patients did not receive adjuvant therapies after surgery. On multivariate analysis, tumor grade, tumor size, and surgical margins were associated with worse survival. Extent of surgery (mastectomy versus lumpectomy) and radiation therapy use were not associated with improved survival. Adjuvant chemotherapy was associated with improved survival in patients with primary tumors 5 cm and greater. Conclusions: The extent of surgery is not associated with improved survival in women with LBA, and patients may consider breast-conservation surgery. Adjuvant therapies are not associated with improved survival, with the exception of possible role of adjuvant chemotherapy in large primary tumors (5 cm or greater). Further clinical studies are needed to determine the impact of these treatments on local control, progression-free survival, and patients’ quality of life. Until then, the findings of our analysis will form basis for the multi-disciplinary discussion of management of women with LBA.
AB - Background: Localized breast angiosarcoma (LBA) is a rare condition with no prospective clinical trials guiding the management of afflicted patients. Management of LBA and the resulting outcomes on a nationwide scale has not been previously examined. Methods: The National Cancer Data Base (NCDB) from 2004 to 2014 identified resected LBA patients. Treatment patterns were compared between three time periods (2004–2007, 2008–2011, and 2012–2014). Demographic and tumor characteristics, as well as treatments received—extent of surgery and adjuvant therapies—were analyzed for association with overall survival after adjustment for covariates. Results: 826 resected localized breast angiosarcoma patients were identified. Mastectomy was the most common surgical approach (86%); over 60% of patients did not receive adjuvant therapies after surgery. On multivariate analysis, tumor grade, tumor size, and surgical margins were associated with worse survival. Extent of surgery (mastectomy versus lumpectomy) and radiation therapy use were not associated with improved survival. Adjuvant chemotherapy was associated with improved survival in patients with primary tumors 5 cm and greater. Conclusions: The extent of surgery is not associated with improved survival in women with LBA, and patients may consider breast-conservation surgery. Adjuvant therapies are not associated with improved survival, with the exception of possible role of adjuvant chemotherapy in large primary tumors (5 cm or greater). Further clinical studies are needed to determine the impact of these treatments on local control, progression-free survival, and patients’ quality of life. Until then, the findings of our analysis will form basis for the multi-disciplinary discussion of management of women with LBA.
KW - Chemotherapy
KW - Localized breast angiosarcoma
KW - Lumpectomy
KW - Mastectomy
KW - National cancer database
KW - Radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85062534183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062534183&partnerID=8YFLogxK
U2 - 10.1007/s10549-019-05172-5
DO - 10.1007/s10549-019-05172-5
M3 - Article
C2 - 30820717
AN - SCOPUS:85062534183
SN - 0167-6806
VL - 175
SP - 409
EP - 418
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -